Tags

Type your tag names separated by a space and hit enter

The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease.
Aliment Pharmacol Ther. 2000 Nov; 14(11):1503-9.AP

Abstract

BACKGROUND

Tegaserod (HTF 919), a 5-HT4 receptor partial agonist, has prokinetic effects that might be useful in decreasing acid reflux in gastro-oesophageal reflux disease (GERD).

METHODS

To investigate the potential clinical utility of tegaserod in GERD, a five-period crossover study (balanced Latin square) was designed to evaluate the efficacy of 4 b.d. doses of tegaserod vs. placebo. Four-hour manometry (1 h fasting and 3 h postprandial) with continuous recording of lower oesophageal sphincter pressure and distal oesophageal pH, was performed at the end of each 2-week treatment period in 19 patients with mild-to-moderate GERD. Recordings were scored for mean lower oesophageal sphincter pressure, number of transient lower oesophageal sphincter relaxations, and distal oesophageal acid exposure.

RESULTS

Tegaserod (1 mg/day and 4 mg/day) caused a more than 50% decrease in acid exposure in the postprandial period in patients with abnormal acid exposure, although only the 1 mg/day tegaserod treatment elicited statistically significant decreasing (P < 0.05) for the entire treatment group (percentage time for which pH < 4: placebo=13%; 1 mg/day dose=5%; 4 mg/day dose=8%). A decreased number of reflux episodes was demonstrated with both the 1 mg/day and 4 mg/day tegaserod doses. There was no apparent effect on mean lower oesophageal sphincter pressure, whilst transient lower oesophageal sphincter relaxations frequency decreased in the 1-2.5 h post-dose.

CONCLUSIONS

Tegaserod in a dose of 1 mg/day causes a significant decrease in postprandial oesophageal acid exposure. The reduction in oesophageal acid exposure with tegaserod treatment may result from enhanced oesophageal acid clearance, improved gastric emptying, and/or reduced transient lower oesophageal sphincter relaxations.

Authors+Show Affiliations

Northwestern University Medical School, Chicago, Illinois 60611, USA. p_kahrilas@northwestern.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11069322

Citation

Kahrilas, P J., et al. "The Effects of Tegaserod (HTF 919) On Oesophageal Acid Exposure in Gastro-oesophageal Reflux Disease." Alimentary Pharmacology & Therapeutics, vol. 14, no. 11, 2000, pp. 1503-9.
Kahrilas PJ, Quigley EM, Castell DO, et al. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14(11):1503-9.
Kahrilas, P. J., Quigley, E. M., Castell, D. O., & Spechler, S. J. (2000). The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics, 14(11), 1503-9.
Kahrilas PJ, et al. The Effects of Tegaserod (HTF 919) On Oesophageal Acid Exposure in Gastro-oesophageal Reflux Disease. Aliment Pharmacol Ther. 2000;14(11):1503-9. PubMed PMID: 11069322.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. AU - Kahrilas,P J, AU - Quigley,E M, AU - Castell,D O, AU - Spechler,S J, PY - 2000/11/9/pubmed PY - 2001/2/28/medline PY - 2000/11/9/entrez SP - 1503 EP - 9 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 14 IS - 11 N2 - BACKGROUND: Tegaserod (HTF 919), a 5-HT4 receptor partial agonist, has prokinetic effects that might be useful in decreasing acid reflux in gastro-oesophageal reflux disease (GERD). METHODS: To investigate the potential clinical utility of tegaserod in GERD, a five-period crossover study (balanced Latin square) was designed to evaluate the efficacy of 4 b.d. doses of tegaserod vs. placebo. Four-hour manometry (1 h fasting and 3 h postprandial) with continuous recording of lower oesophageal sphincter pressure and distal oesophageal pH, was performed at the end of each 2-week treatment period in 19 patients with mild-to-moderate GERD. Recordings were scored for mean lower oesophageal sphincter pressure, number of transient lower oesophageal sphincter relaxations, and distal oesophageal acid exposure. RESULTS: Tegaserod (1 mg/day and 4 mg/day) caused a more than 50% decrease in acid exposure in the postprandial period in patients with abnormal acid exposure, although only the 1 mg/day tegaserod treatment elicited statistically significant decreasing (P < 0.05) for the entire treatment group (percentage time for which pH < 4: placebo=13%; 1 mg/day dose=5%; 4 mg/day dose=8%). A decreased number of reflux episodes was demonstrated with both the 1 mg/day and 4 mg/day tegaserod doses. There was no apparent effect on mean lower oesophageal sphincter pressure, whilst transient lower oesophageal sphincter relaxations frequency decreased in the 1-2.5 h post-dose. CONCLUSIONS: Tegaserod in a dose of 1 mg/day causes a significant decrease in postprandial oesophageal acid exposure. The reduction in oesophageal acid exposure with tegaserod treatment may result from enhanced oesophageal acid clearance, improved gastric emptying, and/or reduced transient lower oesophageal sphincter relaxations. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/11069322/The_effects_of_tegaserod__HTF_919__on_oesophageal_acid_exposure_in_gastro_oesophageal_reflux_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0269-2813&amp;date=2000&amp;volume=14&amp;issue=11&amp;spage=1503 DB - PRIME DP - Unbound Medicine ER -